Literature DB >> 11027426

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer.

O J Cordero1, D Ayude, M Nogueira, F J Rodriguez-Berrocal, M P de la Cadena.   

Abstract

CD26 is an ectoenzyme with dipeptidyl peptidase IV activity expressed on a variety of cell types. Although the function of the high concentration of serum-soluble CD26 (sCD26) is unknown, it may be related to the cleavage of biologically active polypeptides. As CD26 or enzymatic activity levels were previously associated with cancer, we examined the potential diagnostic and prognostic value of preoperative sCD26 measurements by ELISA in colorectal carcinoma patients. We found a highly significant difference between sCD26 levels in healthy donors (mean 559.7 +/- 125.5 microg l(-1)) and cancer patients (mean 261.7 +/- 138.1 microg l(-1)) (P< 0.001). A cut-off at 410 microg l(-1)gave 90% sensitivity with 90% specificity which means that the diagnostic efficiency of sCD26 is higher than that shown by other markers, particularly in patients at early stages. Moreover, sCD26 as a variable is not related with Dukes' stage classification, age, gender, tumour location or degree of differentiation. With a follow-up of 2 years until recurrence, preliminary data show that sCD26 can be managed as a prognostic variable of early carcinoma patients. In addition, the origin of sCD26 is discussed. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027426      PMCID: PMC2363587          DOI: 10.1054/bjoc.2000.1410

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  54 in total

Review 1.  CD26, let it cut or cut it down.

Authors:  I De Meester; S Korom; J Van Damme; S Scharpé
Journal:  Immunol Today       Date:  1999-08

2.  Glycylprolyl beta-naphthylamidase activity in human serum.

Authors:  M Hino; T Nagatsu; S Kakumu; S Okuyama; Y Yoshii; I Nagatsu
Journal:  Clin Chim Acta       Date:  1975-07-09       Impact factor: 3.786

3.  Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients.

Authors:  T Uematsu; M Urade; M Yamaoka
Journal:  J Oral Pathol Med       Date:  1998-03       Impact factor: 4.253

4.  The use of relative operating characteristic (ROC) curves in test performance evaluation.

Authors:  J R Beck; E K Shultz
Journal:  Arch Pathol Lab Med       Date:  1986-01       Impact factor: 5.534

5.  Serum glycylproline p-nitroanilidase activity in blood cancers.

Authors:  K Fujita; M Hirano; K Tokunaga; I Nagatsu; T Nagatsu; S Sakakibara
Journal:  Clin Chim Acta       Date:  1977-12-01       Impact factor: 3.786

6.  Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase.

Authors:  R Underwood; M Chiravuri; H Lee; T Schmitz; A K Kabcenell; K Yardley; B T Huber
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

7.  Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.

Authors:  P Proost; I De Meester; D Schols; S Struyf; A M Lambeir; A Wuyts; G Opdenakker; E De Clercq; S Scharpé; J Van Damme
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

8.  Alpha-L-fucosidase enzyme in the prediction of colorectal cancer patients at high risk of tumor recurrence.

Authors:  J Fernández-Rodríguez; D Ayude; M P de la Cadena; V S Martínez-Zorzano; A de Carlos; A Caride-Castro; G de Castro; F J Rodríguez-Berrocal
Journal:  Cancer Detect Prev       Date:  2000

9.  Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence.

Authors:  S Iwaki-Egawa; Y Watanabe; Y Kikuya; Y Fujimoto
Journal:  J Biochem       Date:  1998-08       Impact factor: 3.387

10.  Immunohistochemical localization of adenosine deaminase complexing protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity.

Authors:  J Ten Kate; J T Wijnen; J Boldewijn; P M Khan; F T Bosman
Journal:  Histochem J       Date:  1985-01
View more
  27 in total

1.  In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.

Authors:  Pei-Jun Liu; Chi-De Chen; Chih-Liang Wang; Yi-Cheng Wu; Chia-Wei Hsu; Chien-Wei Lee; Lien-Hung Huang; Jau-Song Yu; Yu-Sun Chang; Chih-Ching Wu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2015-01-31       Impact factor: 5.911

2.  Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.

Authors:  Silke Retlich; Vincent Duval; Arne Ring; Alexander Staab; Silke Hüttner; Arvid Jungnik; Ulrich Jaehde; Klaus A Dugi; Ulrike Graefe-Mody
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

4.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

5.  Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.

Authors:  Loretta De Chiara; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; Oscar J Cordero; David Martínez-Ares; María Páez de la Cadena
Journal:  BMC Cancer       Date:  2010-06-28       Impact factor: 4.430

6.  Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent.

Authors:  Sarah E Herlihy; Darrell Pilling; Anu S Maharjan; Richard H Gomer
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

7.  Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Authors:  Arpi Nazarian; Kevin Lawlor; San San Yi; John Philip; Mousumi Ghosh; Mariana Yaneva; Josep Villanueva; Alan Saghatelian; Melissa Assel; Andrew J Vickers; James A Eastham; Howard I Scher; Brett S Carver; Hans Lilja; Paul Tempst
Journal:  Mol Cell Proteomics       Date:  2014-07-23       Impact factor: 5.911

Review 8.  Early detection of colon cancer: new tests on the horizon.

Authors:  Akshay K Gupta; Dean E Brenner; D Kim Turgeon
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.

Authors:  H J Choi; J Y Kim; S-C Lim; G Kim; H J Yun; H S Choi
Journal:  Br J Pharmacol       Date:  2015-10-16       Impact factor: 8.739

Review 10.  Colorectal cancer: from prevention to personalized medicine.

Authors:  Gemma Binefa; Francisco Rodríguez-Moranta; Alex Teule; Manuel Medina-Hayas
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.